Funny how an unsolicited bid will suddenly alert Wall Street to the value of a strong biotech.
While Onyx Pharmaceuticals (Nasdaq:ONXX) was generally a pretty well-regarded biotech, the news over the weekend that Amgen (Nasdaq:AMNG) had made a bid, and that management was now soliciting higher offers, has sent the shares rocketing up in pre-market trade. Given its solid collection of oncology/hematology assets, it won't be surprising if Onyx draws a crowd to its bargaining table before declaring a winner.

SEE: The Ups And Downs Of Biotechnology
Good Reporting Triggers A New Era
Financial Post's Barry Critchley offered quite the scoop late Friday when he reported seeing a letter wherein Amgen made a formal bid for Onyx in the amount of $8.7 billion or $120/share. Onyx ultimately acknowledged the bid, but declared it insufficient and that the company was now going to begin an active sales process. To that end, it's worth noting that Onyx's press release acknowledging Amgen's bid made it clear that the company has received other indications of interest.
Who Will Step Up?
Onyx has what almost every pharmaceutical company wants today – a collection of oncology/hematology assets that are of good quality, relatively early in their commercial life-cycle, and likely to offer solid growth in the near term. Accordingly, I don't think Onyx management or investors need to worry about a lack of interest in acquiring this company.
Maybe one of the first companies to consider in any auction process is Bayer – the company's OUS partner for Nexavar and Stivarga. I'm skeptical of the potential that Bayer will get involved. Bayer is pretty rigid when it to return on investment and debt targets, and a bid into the $130s or higher would seriously challenge both of those. While Bayer might like to have the other 50% of profits from Nexavar and Stivarga, Bayer has relatively little direct presence (or assets) in the U.S. and would likely need to do further deals to really leverage a new U.S. presence.

SEE: Evaluating Pharmaceutical Companies
Amgen certainly has to be a name high on the list of potential acquirers. Biotech M&A has long been a market where “if at first you don't succeed...” is very relevant – just because Onyx management didn't like the initial bid doesn't mean the door is closed to a higher offer. Of all the companies potentially interested in Onyx, Amgen may be among the most motivated – Amgen is trying to build an oncology franchise and is presently quite weak in terms of growth, and Onyx would help both issues.
Almost any large pharmaceutical company with a presence in oncology and the US could find some use for Onyx. Novartis (NYSE:NVS), Bristol-Myers (NYSE:BMY), Pfizer (NYSE:PFE) could all fit the bill, and I wouldn't rule out AstraZeneca (NYSE:AZN) which, like Amgen, badly needs near-term growth. I'm also surprised there isn't more initial buzz on Roche (Nasdaq:RHHBY), given the company's huge presence in oncology, its need (arguably) to diversify its oncology assets, and its willingness to pay up for assets.
Last, and certainly not least, are some “mid-majors” with solid oncology footing – Celgene (Nasdaq:CELG) and Gilead (Nasdaq:GILD). Both are strong in hematology, which makes me wonder about the extent to which Onyx would really improve the companies' growth profile over the long-term.
How High Will The Bidding Go?
Although I think Onyx is probably worth about $110 to $125 on its own, the company will clearly go for more than that in a public sale process. Not only do strategic buyers have the opportunity to take out SG&A expenses and leverage complimentary R&D assets, but a strategic buyer may also be able to enhance the long-term revenue potential of Onyx's marketed drugs and pipeline. As such, I could see the price going above $140 and still offering some value for the right buyer.
The Bottom Line
If you don't own Onyx already, this news doesn't really create an investment opportunity. On the other hand, traders may find that trying to play the spread between its open on Monday morning and the eventual deal price is worthwhile. If I were an Onyx shareholder, I'd definitely sit tight – it seems highly improbable to me that the company won't get multiple bids, and I think the odds of the company overplaying its hand such that all of the bidders walk away are relatively low.
Disclosure – As of this writing, the author owns shares of Roche.

Related Articles
  1. Investing

    The Rise of Corporate Venture Capital

    After the success of Google Ventures, corporate venture capital is an increasingly popular diversification and hedging tool for many large corporations.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraPro Nasdaq Biotech

    Obtain information about an ETF offerings that provides leveraged exposure to the biotechnology industry, the ProShares UltraPro Nasdaq Biotech Fund.
  4. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  5. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  7. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  8. Mutual Funds & ETFs

    ETF Analysis: BioShares Biotechnology Products

    Learn more about the BioShares Biotechnology Products fund, an exchange-traded fund that is focused on producers of FDA-approved drugs.
  9. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraShort Nasdaq Biotech

    Learn more about an innovative inverse-leveraged sector exchange-traded fund, or ETF, the ProShares UltraShort Nasdaq Biotechnology fund.
  10. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. Phenotype

    An organism’s observable characteristics or traits.
  5. Pharmacology

    The study of how drugs affect people. More formally, pharmacology ...
  6. Molecular Biology

    The study of biology and biological processes at the fundamental ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!